Precipio, Inc. (NASDAQ: PRPO) will showcase the findings of a joint study with Memorial Sloan‑Kettering on its BCR::ABL1 assay at the 2025 American Society of Hematology (ASH) meeting in Orlando, Florida. The study evaluated 895 patient samples and demonstrated that the assay achieved superior analytical performance and high concordance with two other leading platforms, underscoring the sensitivity of Precipio’s ICE‑COLD PCR technology for detecting low‑frequency variants in blood cancer diagnostics.
The poster presentation and results discussion are scheduled for Monday, December 8, 2025, from 6:00 pm to 8:00 pm in the OCCC room, West Halls B3‑B4. The event will provide a platform for Precipio to highlight how its proprietary technology can improve patient care and streamline laboratory workflows, reinforcing the company’s dual‑engine business model that blends diagnostic services with product commercialization.
Precipio’s Q3 2025 financial results, released earlier this month, showed revenue of $6.8 million—up 30% year‑over‑year and 20% quarter‑over‑quarter—alongside a positive adjusted EBITDA of $469 k, a sharp improvement from $100 k in Q3 2024. Net loss narrowed to $79 k from $626 k a year earlier, and operating cash flow turned positive at $285 k. Management cited these gains as evidence of the company’s growing operational efficiency and the value of its dual‑engine strategy.
CEO Ilan Danieli emphasized that “quarters like this create all kinds of growth opportunities for our company, ones that management intends to seize.” The strong financial performance signals that the ICE‑COLD PCR platform is gaining traction in the market, while the upcoming ASH presentation is expected to accelerate adoption among hematology laboratories and clinicians.
The BCR::ABL1 assay’s high concordance with established platforms positions Precipio as a credible alternative in a competitive landscape dominated by a few large players. By demonstrating superior sensitivity, the company aims to capture a share of the growing market for liquid biopsy and minimal residual disease testing, which is projected to expand as precision oncology becomes standard practice.
Precipio’s dual‑engine model—leveraging revenue from pathology services to fund product development—has been validated by the recent earnings turnaround. The Pathology Services Division generated $6 million in Q3 2025 revenue, a 20% sequential increase, while the Product Division grew 16% to $0.72 million, reflecting momentum behind ICE‑COLD PCR‑based assays.
The ASH presentation will be a key milestone for Precipio, providing clinical validation that can drive broader market adoption and support the company’s long‑term growth strategy.
revised_sentiment_rating
importance
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.